基于多巴胺的高性能超分子生物粘合剂
Maximilian J L Hagemann1, Lewis Chadwick1, Marcus J Drake2
1School of Chemistry, University of Bristol, Bristol, BS8 1TS, UK.
Macromolecular rapid communications
|May 17, 2024
概括
基于多巴胺的新型高分子聚合物提供了卓越的伤口关闭解决方案. 这些先进的生物粘合剂表现出高强度,重新粘合能力和安全性,性能优于当前的手术粘合剂.
科学领域:
- 生物材料科学 生物材料科学
- 聚合物化学 聚合物化学
- 手术创新 在外科创新.
背景情况:
- 是伤口关闭的标准,但存在侵入性和污染的风险.
- 手术粘合剂提供了不那么侵入性的替代品,高分子粘合剂提供了新的解决方案.
- 目前的生物粘合剂在强度和重新粘合性方面存在局限性.
研究的目的:
- 合成和描述使用多巴胺作为自组装单元的新型超分子聚合物.
- 评估这些新材料的粘合性能,机械强度和生物相容性.
- 为了比较这些新型粘合剂与商用手术粘合剂的性能.
主要方法:
- 以多巴胺为基础的聚合物的合成,具有不同的单体料比率和交叉链接水平.
- 机械测试,以确定屈服强度和拉伸性能.
- 评估重新粘附能力,细胞毒性 (细胞活力测定) 和水性环境中的性能.
- 使用良性有机溶剂去除的评估.
主要成果:
- 合成的多巴胺基聚合物作为高效的粘合剂起作用.
- 粘合强度和材料特性可以通过单体比率和交叉连接进行调整.
- 这些材料的强度至少是BioGlue和Tisseel的两倍.
- 证明了显著的重新粘附性,非细胞毒性 (>90%的细胞活力) 和在水性条件下稳定的性能.
- 证实使用乙醇成功去除.
结论:
- 基于多巴胺的高分子聚合物代表了一类有前途的新型生物粘合剂.
- 与现有的选择相比,这些材料提供了优越的机械强度和重新粘附性.
- 它们在潮湿环境中的生物相容性和性能表明它们在手术应用中具有显著的潜在优势.
相关概念视频
01:30Adrenergic Agonists: Direct-Acting Agents
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...
01:25Adrenergic Agonists: Indirect-Acting Agents
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
01:16Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...